Lataa...
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks
Natalizumab (NTZ) is a highly effective disease modifying therapy for the treatment of relapsing forms of multiple sclerosis (MS). Despite evidence to support its use as first-line therapy, risk of NTZ-associated progressive multifocal leukoencephalopathy (PML) has largely contributed to it being re...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3926344/ https://ncbi.nlm.nih.gov/pubmed/24587891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622313514790 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|